A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

This study is testing a combination treatment approach for liver cancer (hepatocellular carcinoma) that cannot be surgically removed. The treatment combines a targeted radiation therapy called Y90-SIRT (tiny radioactive beads delivered directly into the liver's blood supply) with immunotherapy drugs. Researchers want to see if this combination works better than existing options. **You may be eligible if...** - You are aged 18–80 with liver cancer confirmed by imaging or biopsy that cannot be surgically removed - Your liver function is relatively preserved (Child-Pugh class A) - You are in good physical condition (ECOG 0–1) - You have not previously received systemic treatment or radioembolization (Y90) - You do not have cancer outside the liver (except lymph node involvement) - Your blood counts, liver function, and kidneys meet minimum requirements **You may NOT be eligible if...** - Your cancer is too widespread or has spread to blood vessels throughout the liver - You have advanced liver cirrhosis (Child-Pugh class C) - You have serious heart disease or a history of blood clots (stroke, pulmonary embolism) in the past 6 months - You have active hepatitis B, C, or HIV infection - You have had an organ transplant - You have an active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.